HYPR at a glance
Hyperfine Inc (HYPR, SEC CIK 1833769) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as August 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Hyperfine Inc (HYPR) reported revenue of $13.6 million (up 5.2% from FY2024) and a net loss of $35.6 million. Diluted EPS was -$0.43.
- As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Hyperfine Inc (HYPR) shares worth $10.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by HALE BRETT on August 24, 2026 of 7,345 shares at $0.85 per share.
- In the last 90 days, HYPR insiders reported 0 open-market purchases ($0) and 2 open-market sales ($13K) on Form 4, a net sale of $13K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $13.6M
- +5.2% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$13K
- 13F holders
- 21 funds
- $10.6M · +1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New Nasdaq delisting risk: bid price below $1.00 for 30 consecutive business days triggered September 17, 2026 notice
- Compliance deadline: regain $1.00 minimum closing bid price by March 16, 2027
- Capital-markets risk: potential Nasdaq delisting could reduce share liquidity and impair capital raising
- Carried-forward risks: no material changes reported beyond the Nasdaq listing deficiency
Management Discussion & Analysis
- Revenue $6.0M, up 73.4% YoY from $3.4M, driven by device sales growth
- Gross margin 56.7% vs 53.8% YoY, operating loss $7.3M vs $8.9M
- Device sales $5.2M, up 81.4%, outperformed service sales of $2.1M, up 21.3%
- Cash $37.9M; operating cash outflow $22.4M, financing inflow $25.3M, including $13.6M debt proceeds
- Outlook: negative operating cash flows expected; cash and sales expected to fund planned operations for at least 12 months, with tariff and cost headwinds
AI summary of the HYPR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 announced by Hyperfine
- Business update included in accompanying Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 revenue $6.0M, up 73% year over year and 53% sequentially, signaling accelerating Swoop commercial adoption
- Gross margin reached a record 57%, with gross profit up 83% while operating expenses declined 1%, demonstrating operating leverage
Item 7.01: Regulation FD Disclosure
- Preliminary Q3 2026 revenue approximately $6.0 million, described as a company record
- Full-year 2026 revenue outlook reaffirmed at approximately $20 million to $22 million
Item 2.02: Results of Operations and Financial Condition
- Preliminary Q3 2026 revenue approximately $6.0 million, subject to material revision
- Nine-month 2026 revenue approximately $13.8 million, indicating year-to-date operating scale
Item EX-99.2: Item EX-99.2
- Preliminary Q3 revenue $6.0M, up 53% sequentially and 55% YoY, signaling accelerating commercialization
- Preliminary Q3 net cash burn $5.6M, down 29% sequentially, with revenue exceeding cash burn for the first time
Item EX-99.1: Item EX-99.1
- Preliminary Q3 2026 revenue approximately $6.0M, up 53% sequentially, signaling accelerating Swoop commercial adoption
- Net cash burn approximately $5.6M, down 29% sequentially, with revenue exceeding burn for the first time
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq deficiency: HYPR below the $1.00 minimum bid price for 30 consecutive business days
- No immediate delisting: Class A shares continue trading on Nasdaq Global Market under HYPR
AI summaries of HYPR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HYPR
Don't miss the next HYPR filing
- Alerts as it files. A push when HYPR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HYPR, by share count.
- Ask anything. An AI agent that reads every HYPR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HALE BRETT | Sell | Aug 24, 2026 | 7,345 | $0.85 |
| TEISSEYRE THOMAS | Sell | Aug 24, 2026 | 7,345 | $0.85 |
| Wolterman Dan | A | Jun 3, 2026 | 52,600 | - |
| TEISSEYRE THOMAS | Sell | May 26, 2026 | 6,047 | $1.65 |
| HALE BRETT | Sell | May 26, 2026 | 6,047 | $1.65 |
| Fattori Ruth A | A | May 22, 2026 | 157,700 | - |
| Wolterman Dan | A | May 22, 2026 | 157,700 | - |
| ROTHBERG JONATHAN M | A | May 22, 2026 | 157,700 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $12.9M | $13.6M |
| Gross Profit | - | $5.9M | $6.8M |
| Operating Income | - | -$43.2M | -$37.1M |
| Net Income | - | -$40.7M | -$35.6M |
| Gross Margin | - | 45.7% | 49.8% |
| Op. Margin | - | -335.3% | -273.4% |
| Net Margin | - | -315.9% | -262.3% |
| Balance Sheet | |||
| Total Assets | - | $58.9M | $55.3M |
| Equity | $84.4M | $49.0M | $41.0M |
| ROE | - | -83.0% | -86.8% |
| Per Share | |||
| EPS | - | $-0.56 | $-0.43 |
| Cash Flow | |||
| Operating CF | - | -$38.8M | -$27.9M |
| CapEx | $804K | $383K | $1.2M |
Source: XBRL data in Hyperfine Inc (HYPR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HYPR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 21 | $10.6M |
| Q2 2026 | 20 | $17.8M |
| Q1 2026 | 12 | $7.1M |
| Q4 2025 | 14 | $7.4M |
| Q3 2025 | 13 | $9.6M |
| Q2 2025 | 11 | $4.6M |
| Q1 2025 | 11 | $3.4M |
| Q4 2024 | 9 | $4.2M |
- Goldman Sachs Group+56.7K (+166%)
- Bank of America Corp+31.2K (+70%)
- State Street Corp+16.4K (+2%)
- Invesco Ltd+9.0K (+21%)
- Morgan Stanley+7.0K (+17%)
- Renaissance Technologies LLC−230.2K (-24%)
- Two Sigma Investments−180.8K (-55%)
- Citigroup−52.5K (-93%)
- Wells Fargo & Co−47.6K (-64%)
- BlackRock−16.4K (-0%)
- Citadel Advisors LLC+347.1K
- AQR Capital Management+44.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 111 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HYPR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 8-K | Sep 18, 2026 | - | Analysis | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 8-K | May 21, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | - | |
| 8-K | May 12, 2026 | - | - | |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 8-K | Mar 18, 2026 | - | Analysis | - |
| 10-K | Mar 18, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
HYPR SEC filings: frequently asked questions
Are HYPR insiders buying or selling?
In the last 90 days, Hyperfine Inc (HYPR) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $12,545 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold HYPR stock?
As of September 30, 2026, the largest Hyperfine Inc (HYPR) holders among the 13F filers tracked by SignalX were BlackRock ($3.8 million), Vanguard Capital Management LLC ($2.7 million), State Street Corp ($835,000), Alphabet Inc ($728,000), Renaissance Technologies LLC ($578,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HYPR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Hyperfine Inc (HYPR) reported revenue of $13.6 million (up 5.2% from FY2024) and a net loss of $35.6 million. Diluted EPS was -$0.43. The figures come from the XBRL data in the 10-K.
What did HYPR report in its latest 8-K?
Hyperfine Inc (HYPR) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for quarter ended September 30, 2026 announced by Hyperfine.
What are the latest HYPR SEC filings?
Hyperfine Inc (HYPR) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on August 25, 2026.
What is HYPR's SEC CIK number?
Hyperfine Inc (HYPR)'s SEC Central Index Key (CIK) is 1833769. EDGAR lists every HYPR filing under that number.
Ask anything about HYPR
The research agent reads HYPR's filings, financials, insider trades and 13F holders, then answers with sources.